IL-31 monoclonal antibodies and methods of use
There is provided a monoclonal antibody wherein the monoclonal antibody is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from a first group consisting of: a) ATCC Patent Deposit Designation PTA-6815; b) ATCC Patent D...
Gespeichert in:
Hauptverfasser: | , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre ; ger |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | There is provided a monoclonal antibody wherein the monoclonal antibody is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from a first group consisting of: a) ATCC Patent Deposit Designation PTA-6815; b) ATCC Patent Deposit Designation PTA-6816; c) ATCC Patent Deposit Designation PTA-6871; d) ATCC Patent Deposit Designation PTA-6829; and e) ATCC Patent Deposit Designation PTA-6830; or wherein the monoclonal antibody is selected from a second group consisting of: a) ATCC Patent Deposit Designation PTA-6831; b) ATCC Patent Deposit Designation PTA-6872; c) ATCC Patent Deposit Designation PTA-6875; and d) ATCC Patent Deposit Designation PTA-6873; for use in treating a disease selected from the group consisting of prurigo nodularis; cutaneous T cell lymphoma; atopic dermatitis; contact dermatitis; drug-induced allergic reactions; skin-tropic viruses; viral associated pruritis; vitiligo; alopecia aerata; acne rosacea; acne vulgaris; and bullous pemphigoid. |
---|